Decreasing the Incidence of Post-Operative Nausea and Vomiting (PONV) in Bariatric Patients

Completed · Not applicable · Has a placebo group

Conditions studied: Nausea, Vomiting

In brief

The study drug, Aprepitant, is currently used to control chemotherapy induced nausea and vomiting and is also approved for post-operative nausea and vomiting. The investigators' evaluation of it in morbidly obese patients will demonstrate its ability to control nausea and vomiting post-operatively in this subset of patients.

Key facts

Study ID

NCT00956215

Run by

University of Pennsylvania

People needed

125

Starts

2010-05-01

Expected to finish

2012-01-01

Last updated by the study team

2012-02-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects included in this study must be:
• Female
• At least 18 years of age
• Non-smoking
• At high risk for PONV
• Obese with a BMI of at least 45 kg/m2
• Undergoing upper gastrointestinal surgery requiring postoperative opioid analgesia

You may not qualify if…

• Subjects will be excluded if:
• They have a known allergy to Aprepitant or Ondansetron
• They are currently taking Orap (pimozide), Seldane (terfenadine), Hismanal (astemizole), or Propulsid (cisapride)
• They are pregnant
• They are breastfeeding
• They plan on getting pregnant in the 2 months following surgery
• They are not able to receive patient controlled analgesia (PCA) following surgery
• They have a known drug or alcohol abuse problem
• They have chronic nausea and vomiting

Where it is running

• University of Pennsylvania — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.